Mar 07, 2016 12:05 pm UTC| Business
PRINCETON, N.J., March 07, 2016 -- Advaxis, Inc. (NASDAQ:ADXS), a clinical stage biotechnology company developing cancer immunotherapies, today announced dose administration for the first patient in the expansion phase...
Mar 07, 2016 12:05 pm UTC| Business
- MAT2501 (encochleated amikacin) previously designated a Qualified Infectious Disease Product by FDA - - MAT2501 demonstrated oral bioavailability and targeted delivery directly to site of non-tuberculous mycobacteria...
Mar 07, 2016 12:00 pm UTC| Business
OXFORD, United Kingdom, March 07, 2016 -- Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and Clostridium difficile...
Mar 07, 2016 12:00 pm UTC| Business
--Conference Call Scheduled for 8:00 AM ET Today-- HAMPTON, N.J., March 07, 2016 -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that the independent Data Safety and Monitoring Board (DSMB) has determined,...
Sprott Resource Corp. Announces 2015 Annual Results
Mar 07, 2016 12:00 pm UTC| Business
TORONTO, March 07, 2016 -- Sprott Resource Corp. (TSX:SCP)("SRC" or the "Company") today announced its financial results for the year ended December 31, 2015. SummaryNet Asset Value ("NAV") at December 31, 2015 of...
Flexion Therapeutics to Present at Cowen and Company’s 36th Annual Health Care Conference
Mar 07, 2016 12:00 pm UTC| Business
BURLINGTON, Mass., March 07, 2016 -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that Michael Clayman, M.D., President and Chief Executive Officer, will provide a company overview at Cowen and Company’s...
Mar 07, 2016 12:00 pm UTC| Business
Phase 2/3 Pivotal Trial Will Test Intravenous, Oral Capsule and Oral Suspension Formulations of Solithromycin in Pediatric Patients FromAge 2 Months to 17 Years Cempra to Receive $25.5 Million in Funding for the Next...